Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 20-year-old male shares his positive experience with hair regrowth after two years of using finasteride and minoxidil, noting that results can take time and emphasizing the importance of patience. He reports stabilized hair with some regrowth despite aggressive hair loss genes in his family.

The user has been using Minoxidil and Finasteride for hair loss since December 2025, experiencing slower progress compared to others, and is considering additional treatments like Exosomes. Other users share similar experiences with delayed results and suggest patience, while some recommend exploring other treatments or consulting a doctor for underlying causes.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

Microneedling can promote hair growth, but there is uncertainty about the best practices, including needle length, device, and session frequency. Users discuss using needle lengths between 0.5mm and 1.5mm, with some experiencing pinpoint bleeding, and emphasize the need for more reliable resources and guidelines.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

A user has been taking finasteride 1mg for 10 years without side effects but is concerned about high estradiol levels affecting weight loss. Another user suggests using estradiol blockers under medical supervision to manage the levels.

A 20-year-old male has been using finasteride for 7 months and oral minoxidil for 2 months and is planning to check testosterone and estradiol levels. He is seeking advice on additional blood tests to consider.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Hair regrowth with treatments like finasteride, minoxidil, and dutasteride is not linear; shedding phases can occur, causing temporary setbacks. Consistent treatment and evaluating progress at longer intervals, like every 6 months, is recommended for better results.

Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Intermittent fasting may suppress hair follicle regeneration, but opinions vary on its impact on hair loss. Some users report no negative effects or even hair improvement while using treatments like finasteride and minoxidil.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation is about using Maxogen-X, a topical solution containing minoxidil, finasteride, tretinoin, and azelaic acid, for hair loss treatment. Users discuss their experiences, including initial shedding and the hope for thicker hair, while sharing progress updates.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The user experienced significant hair regrowth over 10 months by using 1.5mg oral finasteride and minoxidil daily, along with weekly derma stamping, after a previous hair transplant and initial thinning. The conversation highlights the importance of using DHT blockers post-transplant to maintain results.

The user has been taking oral dutasteride (DUT) and minoxidil (MIN) for 12 months, seeing some hair regrowth but questioning if it's typical for this timeframe. Suggestions include adding microneedling, topical minoxidil, or considering a hair transplant for further improvement.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.

The user experienced significant hair regrowth using spironolactone, estradiol, minoxidil, and finasteride while transitioning. They noted reduced libido and increased grogginess as side effects.

The user is happy with their hair transplant done at age 21 to lower a naturally high hairline, despite minimal thinning. The conversation includes questions about the procedure details and assumptions about using finasteride.